PET/CT imaging of the somatostatin receptor with [18F]AlF-NOTA-octreotide PET/CT: Analysis of impact on tumor staging and therapeutic management

#4050

Introduction: [18F]AlF-NOTA-octreotide ([18F]AlF-OC) is a promising alternative for [68Ga]Ga-DOTA-somatostatin analogues (SSAs) in PET imaging of the somatostatin receptor (SST).

Aim(s): To assess differences in TNM staging and patient management when using [18F]AlF-OC PET/CT in neuroendocrine tumor (NET) patients.

Materials and methods: This is a secondary endpoint analysis of our previously published multicenter study (Pauwels et al., J Nucl Med. 2023;64(4):632-638), which compared lesion detection between [18F]AlF-OC and [68Ga]Ga-DOTA-SSA PET/CT in 75 NET patients. TNM staging was determined for both tracers. For each patient, the blinded [68Ga]Ga-DOTA-SSA or [18F]AlF-OC PET/CT images were presented together with clinical information in random order at a multidisciplinary tumor board. After a decision for patient management was made, the board was presented with the images from the other SST tracer and a decision was made for the second tracer.

Conference:

Presenting Author: Leupe H

Authors: Leupe H, Vandamme T, van den Broeck B, Lybaert W, Dekervel J,

Keywords: Neuroendocrine tumor, nuclear medicine, PET imaging, somatostatin receptor, [68Ga]Ga-DOTA-SSA, [18F]AlF-NOTA-octreotide,